SynthesisWorld journal of gastroenterology2026
High-protein diets and metabolic dysfunction-associated steatotic liver disease: A double-edged sword in liver health.
Synthesis in World journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Non-pharmacological treatment of MASLD.Diabetologia · 2026Review
- Relationship between triglyceride-glucose-derived obesity indices and NAFLD in adolescents: A cross-sectional study.Medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is among the most prevalent chronic liver conditions globally and is closely linked with a range of metabolic disorders. Recently, the high-protein diet (HPD) has garnered attention for its potential benefits in weight management and metabolic health; however, its impact on MASLD remains a subject of debate. This article provided a systematic review of epidemiological studies, clinical trials, and foundational research concerning the role of HPD in MASLD. It examined the mechanisms by which HPD influences liver metabolism, inflammatory responses, and gut microbiota in patients with MASLD and assessed their clinical efficacy. The review revealed that HPD exerts dual effects on MASLD, contingent upon the protein source and consumption levels, and plant-based proteins conferred metabolic advantages. Therefore, it is advised that patients with MASLD prioritize plant-based proteins while moderating animal protein intake. Future research should aim to elucidate the mechanisms underlying HPDs and deploy personalized nutrition approaches that integrate genomic, proteomic, metabolomic, and microbiome profiles to predict individual responsiveness to specific protein sources, thereby enabling precision dietary algorithms for MASLD prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.